Cargando…
Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer
BACKGROUND: T cells engineered to express chimeric antigen receptors (CARs) have established efficacy in the treatment of B-cell malignancies, but their relevance in solid tumors remains undefined. Here we report results of the first human trials of CAR-T cells in the treatment of solid tumors perfo...
Autores principales: | Hege, Kristen M., Bergsland, Emily K., Fisher, George A., Nemunaitis, John J., Warren, Robert S., McArthur, James G., Lin, Andy A., Schlom, Jeffrey, June, Carl H., Sherwin, Stephen A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360066/ https://www.ncbi.nlm.nih.gov/pubmed/28344808 http://dx.doi.org/10.1186/s40425-017-0222-9 |
Ejemplares similares
-
Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer
por: Shu, Runzhe, et al.
Publicado: (2021) -
Effective Targeting of TAG72(+) Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells
por: Murad, John P., et al.
Publicado: (2018) -
The immunogenicity of chimeric antibodies
Publicado: (1989) -
WDR72 regulates vesicle trafficking in ameloblasts
por: Katsura, Kaitlin, et al.
Publicado: (2022) -
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
por: Boyiadzis, Michael M., et al.
Publicado: (2018)